Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.
Kereiakes DJ, Meredith IT, Masotti M, Carrié D, Moreno R, Erglis A, Mehta SR, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe RL, Reitman A, Janssens L, Christen T, Dawkins KD, Windecker S. Kereiakes DJ, et al. Among authors: windecker s. EuroIntervention. 2017 Mar 20;12(16):1987-1994. doi: 10.4244/EIJ-D-16-00643. EuroIntervention. 2017. PMID: 27840326 Free article. Clinical Trial.
Thrombosis and drug-eluting stents: an objective appraisal.
Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PW, Kimura T, Williams DO, Windecker S, Krucoff MW. Holmes DR Jr, et al. Among authors: windecker s. J Am Coll Cardiol. 2007 Jul 10;50(2):109-18. doi: 10.1016/j.jacc.2007.04.032. Epub 2007 May 22. J Am Coll Cardiol. 2007. PMID: 17616294 Review.
Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Cruz-Gonzalez I, Marra S, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: windecker s. EuroIntervention. 2008 May;4(1):77-83. doi: 10.4244/eijv4i1a14. EuroIntervention. 2008. PMID: 19112783
Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy.
Wykrzykowska JJ, Räber L, de Vries T, Bressers M, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Regar E, Jüni P, Windecker S, Serruys PW. Wykrzykowska JJ, et al. Among authors: windecker s. EuroIntervention. 2009 Aug;5(3):310-7. doi: 10.4244/v5i3a49. EuroIntervention. 2009. PMID: 19736154 Free article. Clinical Trial.
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C, Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M, Barbato E, de Vries T, den Drijver AM, Otake H, Meredith L, Toyloy S, Fitzgerald P. Serruys PW, et al. Among authors: windecker s. EuroIntervention. 2010 Jun;6(2):195-205. EuroIntervention. 2010. PMID: 20562069 Clinical Trial.
The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer.
Garg S, Sarno G, Serruys PW, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P, Windecker S. Garg S, et al. Among authors: windecker s. EuroIntervention. 2010 Jun;6(2):233-9. EuroIntervention. 2010. PMID: 20562074 Free article. Clinical Trial.
Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study.
Eshtehardi P, Cook S, Wandel S, Räber L, Wenaweser P, Togni M, Vogel R, Garachemani A, Eberli FR, Lüscher TF, Jüni P, Hess OM, Meier B, Windecker S. Eshtehardi P, et al. Among authors: windecker s. EuroIntervention. 2010 Sep;6(4):467-74. doi: 10.4244/EIJ30V6I4A79. EuroIntervention. 2010. PMID: 20884434 Free article.
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Serruys PW, et al. Among authors: windecker s. Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15. Circulation. 2010. PMID: 21098436
The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer.
Garg S, Wykrzykowska J, Serruys PW, de Vries T, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Tyczynski P, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P, Windecker S. Garg S, et al. Among authors: windecker s. EuroIntervention. 2011 Mar;6(8):928-35. doi: 10.4244/EIJV6I8A162. EuroIntervention. 2011. PMID: 21330239 Free article. Clinical Trial.
1,496 results